口服孕激素拮抗剂onapristone缓释剂在孕激素受体阳性复发性颗粒细胞瘤、低级别浆液性卵巢癌或子宫内膜样子宫内膜癌中的篮式研究
单机构II期篮式研究评估口服孕激素拮抗剂onapristone缓释剂在孕激素受体阳性复发性成人型颗粒细胞瘤、低级别浆液性卵巢癌或子宫内膜样子宫内膜癌患者中的安全性与疗效。2019年5月至2020年5月入组,主要终点为总缓解率。研究未达到主要终点,未观察到客观缓解,但药物在所有3组中耐受性良好。
要点
- 研究未达到主要终点,未观察到客观缓解。
- 成人型颗粒细胞瘤组14例可评估,中位无进展生存期2.8个月,临床获益率35.7%。
- 低级别浆液性卵巢癌组4例可评估,中位无进展生存期4.4个月,临床获益率50%。
核心结论
- 研究未达到主要终点,onapristone缓释剂在所有3组中耐受性良好,但未观察到客观缓解。
研究设计与样本
- 单机构II期篮式研究,纳入孕激素受体阳性且接受过至少1线化疗的成人型颗粒细胞瘤、低级别浆液性卵巢癌或子宫内膜样子宫内膜癌患者。
- 患者于2019年5月至2020年5月入组,孕激素受体状态通过免疫组织化学评估,合格患者需在入组前3年内采集的组织中孕激素受体表达≥1%。
- 患者接受onapristone缓释剂50 mg每日两次直至疾病进展或治疗终止,不良事件按常见不良事件评价标准5.0版分级。
- 主要终点为按实体瘤疗效评价标准1.1版评估的总缓解率,次要终点为缓解持续时间、临床获益率和安全性。
主要发现
- 低级别浆液性卵巢癌组入组5例、子宫内膜样子宫内膜癌组入组1例,两队列均因入组缓慢提前关闭。
- 成人型颗粒细胞瘤组入组14例并完成第一阶段入组,未观察到缓解。
- 低级别浆液性卵巢癌组4例可评估,中位无进展生存期4.4个月(范围1.8-未达到),临床获益率50%(范围6.8%-93.2%)。
- 成人型颗粒细胞瘤组14例均可评估,中位无进展生存期2.8个月(范围1.6-4.9),6个月无进展生存率21.4%(范围5.2%-44.8%),12个月无进展生存率14.3%(范围2.3%-36.6%),临床获益率35.7%(范围12.8%-64.9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 低级别浆液性卵巢癌和子宫内膜样子宫内膜癌队列因入组缓慢提前关闭。
- 研究未达到主要终点,未观察到客观缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the safety and efficacy of the oral progesterone antagonist onapristone extended release (onapristone-XR) in patients with recurrent progesterone receptor (PR)-positive adult-type granulosa cell tumor (aGCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC). METHODS: This single-institution phase II study included patients with PR-positive aGCT, LGSOC, or EEC who received ≥1 prior line of chemotherapy. Patients were enrolled from 5/2019-5/2020. PR status was evaluated via immunohistochemistry. Eligible patients had PR expression ≥1% on tissue collected within 3 years of enrollment. Patients received 50 mg of onapristone-XR twice daily until disease progression or treatment discontinuation. Adverse events were graded by Common Terminology Criteria for Adverse Events version 5.0. The primary endpoint was overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors 1.1. Secondary endpoints were response duration, clinical benefit rate (CBR), and safety. RESULTS: Five patients with LGSOC and 1 with EEC enrolled, but both cohorts closed early due to slow accrual. Fourteen patients with aGCT enrolled and completed stage 1 accrual. No responses were observed. Four patients with LGSOC were evaluable, with median PFS of 4.4 months (range, 1.8-NE) and CBR of 50% (range, 6.8%-93.2%). All 14 patients with aGCT were evaluable, with median PFS of 2.8 months (range, 1.6-4.9), 6-month PFS rate of 21.4% (range, 5.2%-44.8%), 12-month PFS rate of 14.3% (range, 2.3%-36.6%), and a CBR of 35.7% (range, 12.8%-64.9%). CONCLUSIONS: The study did not meet its primary endpoint. While onapristone-XR was well tolerated in all 3 arms, no objective responses were observed.
引用
- Andres S, Finch L, Iasonos A, et al. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer. Gynecol Oncol. 2024. PMID: 38991472. doi:10.1016/j.ygyno.2024.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。